Skip to content
The Nexus
DossierENTITY

VERVE-102

Coverage of VERVE-102 in the Nexus archive.

Earliest in view: May 28 · 13:39 UTCMost recent: May 28 · 13:39 UTC
Co-mentioned in this coverage
New England Journal of Medicineorganization1low-density lipoproteintopic1gene-editing therapytopic1LDLtopic1
Recent coverage
  • HEALTHMay 28 · 13:39 UTCARS TECHNICA
    Bad cholesterol slashed 62% by single dose of gene-editing drug in small trial

    An experimental gene-editing drug, VERVE-102, showed a 62% reduction in LDL cholesterol in a Phase I trial with 35 patients, with no serious adverse events reported. The treatment demonstrated sustained effectiveness over 18 months, though a temporary mild liver enzyme increase was observed.